Genentech's Avastin Labeling Adds Warning On Thromboembolic Events

Updated labeling includes warning on arterial thromboembolic events described in August "Dear Healthcare Provider" letter. Patients treated with Avastin plus chemotherapy had a 4.4% incidence of thromboembolic events versus 1.9% in patients on chemotherapy alone.